Drug intelligence / Profile preview

PK061

Development stage: Preclinical
Lead developer: PharmaKure
Modality: Small Molecules
Administration: Oral

Overview

**PK061** is a PharmaKure proprietary fixed-dose formulation of two undisclosed existing drugs, described by the company as combining an antidepressant and an antipsychotic. It is intended for early and mild Alzheimer’s disease and is designed to disaggregate previously formed toxic oligomeric aggregates of amyloid-beta and tau proteins. PharmaKure has also identified brain fog associated with long COVID and post-traumatic stress disorder as potential additional indications. ([pharmakure.com](https://pharmakure.com/pk061/))

Targets

Aβ (Amyloid-beta peptides and aggregates)TauO (Microtubule-associated protein tau oligomer)

Beyond the preview

Go deeper on PK061.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PK061.

Explore the full profile